Current role
Biotechnology · Healthcare
CEO, Board Member, Chief Accounting Officer
2024-10-15–present
Robert Connelly
Board Member
Elicio Therapeutics, Inc. (ELTX)Chief Accounting Officer
Elicio Therapeutics, Inc. (ELTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Elicio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELTX alertsAbout Robert Connelly
Robert Connelly is recorded as Chief Accounting Officer at Elicio Therapeutics, Inc. (ELTX) since October 15, 2024 and CEO and Board Member at Elicio Therapeutics, Inc. (ELTX). The newest filing on record that lists Robert Connelly as CEO and Board Member at Elicio Therapeutics, Inc. (ELTX) is dated October 9, 2026. Elicio Therapeutics, Inc. reported in an 8-K filed October 17, 2024 that Robert Connelly was appointed Principal Accounting Officer and Principal Financial Officer, effective October 15, 2024. Elicio Therapeutics, Inc. reported in an 8-K filed June 2, 2023 that Robert Connelly was appointed Chief Executive Officer, President and Class I Director, effective June 1, 2023. The proxy statement of Elicio Therapeutics, Inc. reports total compensation of $1,887,660 for Robert Connelly in fiscal 2025, including a base salary of $632,700. Disclosed compensation is on record for 4 fiscal years. Elicio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Elicio Therapeutics, Inc. includes Julian Adams (Chairman), Julian Adams, Ph.D. (Chairman and Board Member), Brian Piekos (CFO) and 7 others.
“On October 15, 2024, Elicio Therapeutics, Inc. (the "Company") appointed Robert Connelly as the Company's Principal Accounting Officer and Principal Financial Officer effective October 15, 2024.”
“At the effective time of the Merger, the Company's board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers”
Affiliation history
-
Current
2024-10-15–present
-
Current
Start not stated–present
Last confirmed October 9, 2026
-
Current
Start not stated–present
Last confirmed October 9, 2026
Company network
Leadership on record at Elicio Therapeutics, Inc.
- Julian Adams Chairman
- Julian Adams, Ph.D. Chairman, Board Member
- Brian Piekos CFO
- Preetam Shah, Ph.D., M.B.A. CFO, Chief Accounting Officer
- Jennifer J. Rhodes General Counsel
- Allen R. Nissenson Board Member
- Allen R. Nissenson, M.D. Board Member
- Assaf Segal Board Member
- Carol Ashe Board Member
- Jay R. Venkatesan Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Elicio Therapeutics, Inc. (ELTX) | President, Chief Executive Officer, and Director | $632,700 | $1,887,660 |
| 2024 | Elicio Therapeutics, Inc. (ELTX) | President, Chief Executive Officer, and Director | $608,400 | $2,036,441 |
| 2023 | Elicio Therapeutics, Inc. (ELTX) | President, Chief Executive Officer, and Director | $498,750 | $678,300 |
| 2022 | Elicio Therapeutics, Inc. (ELTX) | President, Chief Executive Officer, and Director | $475,000 | $1,256,040 |